Tests a wearable device before surgery in people with newly found glioblastoma
Tests the TTFields device before surgery and radiotherapy in adults with glioblastoma.
Plain-language title generated from the registry record
Registry title: Preoperative Preradiotherapy TTFields
Key facts
- Where
- Manchester, United KingdomSee the site
Where in United Kingdom
- The Christie NHS Foundation TrustManchester, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Christie NHS Foundation Trust
- Trial code
- NCT06136611
- Record updated
- 8 May 2026
- Original description
PreOperative PreRAdIotherapy Tumour Treating Fields (PORTRAIT) is a Phase I study that will test the safety and feasibility of Optune administered preoperatively and preradiotherapy in patients with a new radiological diagnosis of glioblastoma (GBM). Participants will be required to undergo additional MRI sequencing scans and provide blood, tear fluid and tissue samples over a maximum of 6 months. After the study patients will follow their standard treatment pathway.Read full original descriptionShow less
Preoperative Preradiotherapy TTFields (PORTRAIT)
PreOperative PreRAdIotherapy Tumour Treating Fields (PORTRAIT) is a Phase I study that will test the safety and feasibility of Optune administered preoperatively and preradiotherapy in patients with a new radiological diagnosis of glioblastoma (GBM). Participants will be required to undergo additional MRI sequencing scans and provide blood, tear fluid and tissue samples over a maximum of 6 months. After the study patients will follow their standard treatment pathway.
Inclusion: Patient is aged >35 years (age range of more likely to suffer from an IDHwt World Health Organisation (WHO) grade 4 astrocytoma)*; Patient is male or female; Patient has a new radiological diagnosis of glioblastoma; Patient has a performance status judged by WHO, Eastern Cooperative Oncology Group (ECOG) score = 0-1; Patient has been reviewed by Neuro-oncology multidisciplinary team (MDT - neurosurgeon, clinical oncologist, radiologist and pathologist); MDT consensus that offering study entry is clinically appropriate and safe i.e. patient unlikely to come to harm (e.g. hydrocephalus) from delayed surgery and pre-operative Optune based on available clinical information and imaging; PI has confirmed at the first clinic visit that study entry is clinically appropriate and safe (e.g. lack of severe and debilitating symptoms of raised intracranial pressure); There is intention to treat the patient with surgical resection and postoperative adjuvant therapy as per current standard of care (40Gy/15 fr or 60Gy/30fr); Patient has adequate haematological and biochemical parameters for surgery and contrast agent administration (full blood count and coagulation profile deemed acceptable by clinical team, eGFR >30ml/min); Patient has mental capacity to consent for treatment; Patient is able and willing to give informed consent; Criteria specific to the experimental arm:; Patient is able and willing to comply with study protocol requirements to continuously shave their head; Patient is able and willing to comply with study protocol requirements to wear Optune equipment for the required duration.
Exclusion: Patients with uncontrolled seizures; Patients have a suspicion of other tumour on CT body scan or known malignancy except non-melanoma skin cancer, completely resected or prostate cancer (with Prostate Specific Antigen of less than or equal to 0.1 ng/ml) within the past three years; Patients have contraindications to contrast-enhanced MRI scanning (e.g. claustrophobia, gadolinium allergy); Patients are due to undergo a planned biopsy procedure only.